Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 178

1.

Family history of convulsions and use of pertussis vaccine.

Livengood JR, Mullen JR, White JW, Brink EW, Orenstein WA.

J Pediatr. 1989 Oct;115(4):527-31.

PMID:
2552066
2.

History of convulsions and use of pertussis vaccine.

Stetler HC, Orenstein WA, Bart KJ, Brink EW, Brennan JP, Hinman AR.

J Pediatr. 1985 Aug;107(2):175-9.

PMID:
3874940
3.

Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.

Bisgard KM, Rhodes P, Connelly BL, Bi D, Hahn C, Patrick S, Glodé MP, Ehresmann KR; Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. kbisgard@cdc.gov.

Pediatrics. 2005 Aug;116(2):e285-94.

PMID:
16061582
4.

Adverse events following immunization with DTP vaccine.

Stetler HC, Mullen JR, Brennan JP, Orenstein WA, Bart KJ, Hinman AR.

Dev Biol Stand. 1985;61:411-21.

PMID:
3879686
6.
7.

The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine.

Barlow WE, Davis RL, Glasser JW, Rhodes PH, Thompson RS, Mullooly JP, Black SB, Shinefield HR, Ward JI, Marcy SM, DeStefano F, Chen RT, Immanuel V, Pearson JA, Vadheim CM, Rebolledo V, Christakis D, Benson PJ, Lewis N; Centers for Disease Control and Prevention Vaccine Safety Datalink Working Group.

N Engl J Med. 2001 Aug 30;345(9):656-61.

9.
10.

Active surveillance of vaccine safety: a system to detect early signs of adverse events.

Davis RL, Kolczak M, Lewis E, Nordin J, Goodman M, Shay DK, Platt R, Black S, Shinefield H, Chen RT.

Epidemiology. 2005 May;16(3):336-41.

PMID:
15824549
11.

[Safety surveillance in the National Vaccination Programme; fewer adverse events with the DTP-IPV-Hib vaccine after the transition to an acellular pertussis component in 2005].

van der Maas NA, David S, Kemmeren JM, Vermeer-de Bondt PE.

Ned Tijdschr Geneeskd. 2007 Dec 8;151(49):2732-7. Dutch.

PMID:
18225797
12.

A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.

Zangwill KM, Eriksen E, Lee M, Lee J, Marcy SM, Friedland LR, Weston W, Howe B, Ward JI.

Pediatrics. 2008 Dec;122(6):e1179-85. doi: 10.1542/peds.2008-1977.

PMID:
19047220
15.

The safety of acellular pertussis vaccine vs whole-cell pertussis vaccine. A postmarketing assessment.

Rosenthal S, Chen R, Hadler S.

Arch Pediatr Adolesc Med. 1996 May;150(5):457-60.

PMID:
8620224
16.

Infants and children with convulsions and hypotonic-hyporesponsive episodes following diphtheria-tetanus-pertussis immunization: follow-up evaluation.

Baraff LJ, Shields WD, Beckwith L, Strome G, Marcy SM, Cherry JD, Manclark CR.

Pediatrics. 1988 Jun;81(6):789-94.

PMID:
3259305
17.

Vaccine Safety Datalink project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team.

Chen RT, Glasser JW, Rhodes PH, Davis RL, Barlow WE, Thompson RS, Mullooly JP, Black SB, Shinefield HR, Vadheim CM, Marcy SM, Ward JI, Wise RP, Wassilak SG, Hadler SC.

Pediatrics. 1997 Jun;99(6):765-73.

PMID:
9164767
18.

Reactogenicity of infant whole cell pertussis combination vaccine compared with acellular pertussis vaccines with or without simultaneous pneumococcal vaccine in the Netherlands.

David S, Vermeer-de Bondt PE, van der Maas NA.

Vaccine. 2008 Oct 29;26(46):5883-7. doi: 10.1016/j.vaccine.2008.07.105. Epub 2008 Sep 4.

PMID:
18775463
19.

Workshop on neurologic complications of pertussis and pertussis vaccination.

Menkes JH, Kinsbourne M.

Neuropediatrics. 1990 Nov;21(4):171-6.

PMID:
1981251
20.

Supplemental Content

Support Center